Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

Fig. 3

Clinical efficacy parameters (combined b.i.d. and t.i.d. dosing). Adjusted mean change from baseline and unadjusted box and whisker plot of unadjusted change from baseline by treatment over time. a C-reactive protein. b Swollen joint count (28). c Tender joint count (28). d Patient assessment of joint pain. b.i.d., twice daily; CRP, C-reactive protein; t.i.d., three times daily

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us